Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2011 1
2012 2
2013 1
2014 1
2015 2
2017 1
2018 2
2019 1
2020 4
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Relevance of Myopenia and Myosteatosis in Colorectal Cancer.
Okugawa Y, Kitajima T, Yamamoto A, Shimura T, Kawamura M, Fujiwara T, Mochiki I, Okita Y, Tsujiura M, Yokoe T, Ohi M, Toiyama Y. Okugawa Y, et al. Among authors: fujiwara t. J Clin Med. 2022 May 6;11(9):2617. doi: 10.3390/jcm11092617. J Clin Med. 2022. PMID: 35566740 Free PMC article. Review.
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Yagi A, D'Alessandro VF, Yasuma T, Furuhashi K, Saiki H, Okano T, Tomaru A, Tanigawa M, D'Alessandro-Gabazza CN, Gabazza EC, Yoshida M, Hataji O, Ibata H, Kobayashi T. Nishimura T, et al. Among authors: fujiwara t. Cancers (Basel). 2022 Aug 16;14(16):3953. doi: 10.3390/cancers14163953. Cancers (Basel). 2022. PMID: 36010946 Free PMC article.
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: fujiwara t. Target Oncol. 2024 Apr 13. doi: 10.1007/s11523-024-01048-x. Online ahead of print. Target Oncol. 2024. PMID: 38613731
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.
Nishimura T, Fujiwara T, Fujimoto H, Tarumi H, Tsuji C, Iwanaka S, Sakakura Y, Naito M, Okugawa Y, Yasuma T, Gabazza EC, Oomoto Y, Kobayashi T, Ibata H. Nishimura T, et al. Among authors: fujiwara t. Thorac Cancer. 2023 Mar;14(7):709-713. doi: 10.1111/1759-7714.14807. Epub 2023 Jan 29. Thorac Cancer. 2023. PMID: 36710365 Free PMC article.
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Furuhashi K, Yagi A, Saiki H, Yasuma T, Okano T, Tomaru A, Tanigawa M, Yoshida M, Hataji O, Ibata H, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T. Nishimura T, et al. Among authors: fujiwara t. Cancer Med. 2024 Apr;13(8):e7188. doi: 10.1002/cam4.7188. Cancer Med. 2024. PMID: 38629295 Free PMC article.
26 results